EP Vantage Medtech 2016 in Review
The annual EP Vantage Medtech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the medtech sector during 2016.
2016 was a year of enormous change on the political stage. For the medical device industry, though, it was fairly quiet, with the pyrotechnics of 2015 a fast-fading memory.
Key findings include:
- The total value of M&A deals fell to $42bn, far below 2015’s total of $128bn
- Medtech companies raised a total of $3.7bn in 2016, down slightly from the year before, but the number of rounds continues to decline steeply
- At 38 in 2016, premarket approvals and humanitarian device exemptions saw a 25% decline from 2015; but de novo clearances were up, with 24 last year compared with 18 in 2015.
In the medtech sphere the venture funding climate is getting deeper into an endless winter” said report author Elizabeth Cairns. “While there are some rich rounds, even in the early stages, most companies are struggling to find growth capital
